Literature DB >> 8988238

Plasma tumor necrosis factor-a (TNF-a) levels in Gaucher disease.

H Michelakakis1, C Spanou, A Kondyli, E Dimitriou, S Van Weely, C E Hollak, M H Van Oers, J M Aerts.   

Abstract

Tumor necrosis factor-a (TNF-a) levels were measured in the plasma of patients with different types of Gaucher disease (GD) and patients with other lysosomal storage diseases. The highest TNF-a levels were observed in the most severe neuronopathic type of GD, exceeding those found in healthy individuals as well as patients with other lysosomal disorders. Type I GD cases showed a wide range of TNF-a levels ranging from normal to 2.5 x the highest control value. TNF-a is a pleiotropic cytokine produced mainly by activated macrophages. Our data suggest that it may play a role in the pathophysiology of GD disease.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8988238     DOI: 10.1016/s0925-4439(96)00056-7

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  26 in total

1.  Neonatal cholestasis as initial manifestation of type 2 Gaucher disease: a continuum in the spectrum of early onset Gaucher disease.

Authors:  Abdallah F Elias; Maria Ronningen Johnson; John K Boitnott; David Valle
Journal:  JIMD Rep       Date:  2011-12-11

2.  Global gene expression profile progression in Gaucher disease mouse models.

Authors:  You-Hai Xu; Li Jia; Brian Quinn; Matthew Zamzow; Keith Stringer; Bruce Aronow; Ying Sun; Wujuan Zhang; Kenneth D R Setchell; Gregory A Grabowski
Journal:  BMC Genomics       Date:  2011-01-11       Impact factor: 3.969

Review 3.  Exploring genetic modifiers of Gaucher disease: The next horizon.

Authors:  Brad A Davidson; Shahzeb Hassan; Eric Joshua Garcia; Nahid Tayebi; Ellen Sidransky
Journal:  Hum Mutat       Date:  2018-09-11       Impact factor: 4.878

4.  The pharmacological chaperone isofagomine increases the activity of the Gaucher disease L444P mutant form of beta-glucosidase.

Authors:  Richie Khanna; Elfrida R Benjamin; Lee Pellegrino; Adriane Schilling; Brigitte A Rigat; Rebecca Soska; Hadis Nafar; Brian E Ranes; Jessie Feng; Yi Lun; Allan C Powe; David J Palling; Brandon A Wustman; Raphael Schiffmann; Don J Mahuran; David J Lockhart; Kenneth J Valenzano
Journal:  FEBS J       Date:  2010-02-10       Impact factor: 5.542

5.  Systemic inflammation in glucocerebrosidase-deficient mice with minimal glucosylceramide storage.

Authors:  Hiroki Mizukami; Yide Mi; Ryuichi Wada; Mari Kono; Tadashi Yamashita; Yujing Liu; Norbert Werth; Roger Sandhoff; Konrad Sandhoff; Richard L Proia
Journal:  J Clin Invest       Date:  2002-05       Impact factor: 14.808

Review 6.  Sphingolipids and cell signalling.

Authors:  P Fredman
Journal:  J Inherit Metab Dis       Date:  1998-08       Impact factor: 4.982

7.  Gaucher iPSC-derived macrophages produce elevated levels of inflammatory mediators and serve as a new platform for therapeutic development.

Authors:  Leelamma M Panicker; Diana Miller; Ola Awad; Vivek Bose; Yu Lun; Tea Soon Park; Elias T Zambidis; Judi A Sgambato; Ricardo A Feldman
Journal:  Stem Cells       Date:  2014-09       Impact factor: 6.277

Review 8.  Molecular regulations and therapeutic targets of Gaucher disease.

Authors:  Yuehong Chen; Neetu Sud; Aubryanna Hettinghouse; Chuan-Ju Liu
Journal:  Cytokine Growth Factor Rev       Date:  2018-04-11       Impact factor: 7.638

9.  Severe impairment of regulatory T-cells and Th1-lymphocyte polarization in patients with Gaucher disease.

Authors:  Christos Sotiropoulos; George Theodorou; Constantina Repa; Theodoros Marinakis; Eugenia Verigou; Elena Solomou; Marina Karakantza; Argiris Symeonidis
Journal:  JIMD Rep       Date:  2014-10-12

10.  Abnormal nonstoring capillary endothelium: a novel feature of Gaucher disease. Ultrastructural study of dermal capillaries.

Authors:  Helena Hůlková; Helena Poupetová; Klaus Harzer; Pramod Mistry; Johannes M F G Aerts; Milan Elleder
Journal:  J Inherit Metab Dis       Date:  2010-01-05       Impact factor: 4.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.